Fawaz Abdallah, Suliman Mouhamad, Robin Mor, Brikman Shay, Shabshin Nogah, Novofastovsky Irina, Egbaria Mohammad, Mader Reuven, Bieber Amir
Rheumatic Diseases Unit, Emek Medical Center, Afula, Israel.
Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Can Geriatr J. 2024 Sep 5;27(3):268-274. doi: 10.5770/cgj.27.724. eCollection 2024 Sep.
Only few studies addressed the topic of Fibromyalgia Syndrome (FMS) effects on geriatric population quality of life and drug usage. The objective of this study was to demonstrate the significant impact of FMS in terms of quality of life (QOL) in geriatric aged patients.
80 patients were studied, 40 with FMS according to FMS 2016 classification criteria, and 40 non-FMS controls. The patients were all above the age of 65 years. The FMS and control group completed Widespread Pain Index (WPI) and Symptom Severity Score (SSS). Three questionnaires, Fibromyalgia Impact Questionnaire (FIQ), Short Form (SF-36) Questionnaire, and Health Assessment Questionnaire Disability Index (HAQ-DI) were completed. These with additional medical records were used to classify symptoms and severity in both groups.
Fibromyalgia patients demonstrated significant higher disability scores, (FIQ of 79.5 vs. 33.9, <.01, and HAQ-DI of 2.00 vs. 1.00, <.01 for FMS vs. non-FMS, respectively), and lower social functioning in comparison to non-FMS controls (SF-36 of social functioning 0.31 vs. 0.92, <.01 for FMS vs. non-FMS, respectively). The FMS group had a higher use of pain management medications (opioid use of 12 patients vs. 0, <.01, use of non-steroidal anti-inflammatory drugs by 11 FMS patients vs. 4 non-FMS controls, <.01).
Patients with FMS older than 65 years of age demonstrate poorer outcomes and worse symptoms in comparison to matched-aged non-FMS control group. An association was found between FMS and the effect on the quality of life in this population.
仅有少数研究探讨了纤维肌痛综合征(FMS)对老年人群生活质量和药物使用的影响。本研究的目的是证明FMS在老年患者生活质量(QOL)方面的重大影响。
对80例患者进行了研究,其中40例根据2016年FMS分类标准诊断为FMS,40例为非FMS对照组。所有患者年龄均在65岁以上。FMS组和对照组完成了广泛性疼痛指数(WPI)和症状严重程度评分(SSS)。完成了三份问卷,即纤维肌痛影响问卷(FIQ)、简短形式(SF-36)问卷和健康评估问卷残疾指数(HAQ-DI)。这些问卷以及额外的病历用于对两组的症状和严重程度进行分类。
与非FMS对照组相比,纤维肌痛患者的残疾评分显著更高(FMS组的FIQ为79.5,而非FMS组为33.9,P<0.01;FMS组的HAQ-DI为2.00,而非FMS组为1.00,P<0.01),社会功能更低(FMS组社会功能的SF-36评分为0.31,而非FMS组为0.92,P<0.01)。FMS组使用疼痛管理药物的比例更高(12例FMS患者使用阿片类药物,而非FMS组为0例,P<0.01;11例FMS患者使用非甾体抗炎药,而非FMS对照组为4例,P<0.01)。
与年龄匹配的非FMS对照组相比,65岁以上的FMS患者预后更差,症状更严重。在该人群中发现FMS与生活质量的影响之间存在关联。